Green Thumb Industries Reports Modest Q2 2026 Growth Amid Strategic Investments and Market Shifts
Green Thumb Industries (GTII) posted second-quarter 2026 financial results showing steady revenue progression despite persistent pricing pressures in key cannabis markets. The Chicago-based company reported $306.7 million in revenue for the quarter ended June 30, 2026, representing a 4.6% increase compared to the same period in 2025. This growth occurred alongside significant operational investments and evolving regulatory developments that position the company for future expansion.
Financial Performance Highlights
While top-line growth was modest, GTII demonstrated improving profitability metrics through strategic cost management and benefit from federal policy shifts. GAAP net income reached $4.9 million ($0.02 per basic and diluted share), marking a turnaround from a $0.6 million net loss in the prior-year quarter. This improvement was driven partly by the Department of Justice’s reclassification of state-legal medical cannabis to Schedule III under the Controlled Substances Act, which ended the application of IRS Section 280E for portions of the business effective April 28, 2026. The change reduced income tax expense to $12.5 million from $21.6 million year-over-year.
Operational profitability showed resilience, with normalized EBITDA—a non-GAAP measure adding back brand licensing fees, stock-based compensation, and certain non-operating items—totaling $84.3 million, or 27.5% of revenue. This compared favorably to $82.7 million (28.2% of revenue) in Q2 2025. The company generated $29.0 million in cash flow from operations during the quarter and ended June with $283.6 million in cash reserves.
Strategic Initiatives and Market Developments
GTII highlighted several state-level advancements supporting its long-term growth strategy. Virginia authorized adult-use cannabis sales beginning July 1, 2027, where the company has operated since 2021 and holds one of five vertically integrated medical cannabis licenses, six RISE dispensaries, and a grower-processor facility. In New Jersey, adult-use sales launched at the RISE Dispensary in Paramus on July 13, 2026, while a new RISE location opened in Hanover, Pennsylvania, on July 31, 2026.
The company also noted progress in hemp policy, citing Ohio as an example where regulatory changes are shifting consumers from unregulated intoxicating hemp products toward licensed cannabis channels. GTII’s leadership suggested this trend could create lasting opportunities for THC beverages in mainstream markets, favoring operators with established scale, brands, and retail presence.
Operational Context and Capital Allocation
Revenue growth was primarily driven by retail sales in Minnesota following adult-use legalization in September 2025, alongside continued gains in Connecticut, Florida, and Ohio. These increases were partially offset by price compression and heightened competition in other markets. Overall retail revenue rose 3.6% year-over-year, though comparable-store sales (for locations open at least 12 months) decreased 1.1% across 103 stores.
Gross profit declined to $137.9 million (45.0% of revenue) from $146.3 million (49.9% of revenue) in Q2 2025, a shift GTII attributed to RYTHM brand licensing fees incurred during the period and ongoing price pressures. Selling, general, and administrative expenses increased to $117.9 million (38.4% of revenue) from $106.8 million (36.4% of revenue) year-over-year, reflecting deliberate investments in compensation and benefits to support talent retention and execution.
Capital allocation remained active, with GTII repurchasing the equivalent of approximately 7.9 million subordinate voting shares for $48.3 million at an average price of $6.11 per share during the quarter. To date, the company has bought back roughly 29.5 million shares for $203.4 million (average price $6.90/share), with $62.3 million remaining under its current authorization through September 22, 2026.
Leadership Perspective
Founder, Chairman, and CEO Ben Kovler emphasized the company’s disciplined approach: “There is real momentum in the business, and we are building on it with a solid balance sheet. Consumers continue to choose cannabis, and our decisions follow the consumer.” He highlighted Virginia and Texas as key future markets, noting these states represent approximately 12% of the U.S. population.
President Anthony Georgiadis pointed to strong brand performance in core states: “In Illinois, Pennsylvania, Ohio, Maryland, and Minnesota, we are especially proud of our brand performance, retaining the number one share position in each state.” He acknowledged that increased team investments temporarily impacted EBITDA margins but framed them as essential for long-term success in an evolving industry.
The company operates RISE Dispensaries across over 120 locations in 14 U.S. markets, manufacturing branded products including RYTHM, Dogwalkers, incredibles, Beboe, &Shine, Doctor Solomon’s, and Good Green. GTII employs approximately 4,900 people nationwide.
For complete financial details and non-GAAP reconciliations, refer to the original press release.
